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Abstract
Background: Minocycline prevents the development of neuropathic and inflammatory pain by inhibiting
microglial activation and postsynaptic currents. But, how minocycline obviates acute visceral pain is unclear. The
present study investigated whether minocycline had an any antinociceptive effect on acetic acid-induced acute
abdominal pain after intraperitoneal (i.p.) administration of saline or minocycline 1 hour before acetic acid injection
(1.0%, 250 μl, i.p.).
Results: Minocycline (4, 10, or 40 mg/kg) significantly decreased acetic acid-induced nociception (0-60 minutes
post-injection) and the enhancement in the number of c-Fos positive cells in the T5-L2 spinal cord induced by
acetic acid injection. Also, the expression of spinal phosphorylated extracellular signal-regulated kinase (p-ERK)
induced by acetic acid was reduced by minocycline pre-administration. Interestingly, intrathecal introduction of
PD98059, an ERK upstream kinase inhibitor, markedly blocked the acetic acid-stimulated pain responses.
Conclusions: These results demonstrate that minocycline effectively inhibits acetic acid-induced acute abdominal
nociception via the inhibition of neuronal p-ERK expression in the spinal cord, and that minocycline may have
therapeutic potential in suppressing acute abdominal pain.
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Background
Minocycline is a second-generation tetracycline antibio-
tic derivative that effectively crosses the blood-brain bar-
rier [1], and which has a proven safety record in humans
[2]. Minocycline has anti-inflammatory and neuropro-
tective effects in animal models of cerebral ischaemia
[3,4], traumatic injury [5], glutamate-induced neurotoxi-
city [6], experimental autoimmune encephalonmyelitis
[7], Huntington’s disease [8] and Parkinson’sd i s e a s e
[2,9,10]. Minocycline’s efficacy has been bolstered by
studies showing decreased secondary neuronal damage
via the inhibition of microglial activation. Recently, it
has been demonstrated that this minocycline-mediated
microglial inhibition attenuates the development of pain
hypersensitivity by inhibiting proinflammatory cytokine
expression in rat models of both neuropathic pain and
spinal immune activation by intrathecal human immu-
nodeficiency virus-1 (HIV-1) gp120 [11,12]. Also, mino-
cycline completely reverses mechanical hyperalgesia in
diabetic rats through microglia-induced changes in the
expression of the potassium chloride co-transporter 2
(KCC2) in the spinal cord [13]. In addition, we con-
firmed that minocycline attenuates tactile hypersensitiv-
ity following the trigeminal sensory nerve injury by
inhibiting microglial p38 mitogen activated protein
kinase (MAPK) activation [14], and that minocycline
markedly reduced formalin-induced inflammatory pain
by inhibition of excitatory postsynaptic currents (EPSCs)
i nt h es u b s t a n t i ag e l a t i n o s a[ 1 5 ] .T h e s ef i n d i n g sr a i s e
the possibility of the potential of minocycline as an
analgesic for other types of pain models.
Visceral pain is the most common form of pain pro-
duced by disease, for which medical care is sought. Despite
the conventional belief that visceral pain is a variant of
somatic pain, it differs in neurological mechanisms and
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any medium, provided the original work is properly cited.transmission pathways. Visceral pain is characterized by
referral hyperalgesia and also it is not always linked to tis-
sue injury [16,17]. Also, visceral pain that reflects the
enhanced perception of physiological signals from the gut
and/or the enhanced perception of experimental visceral
stimuli along with hypervigilance to these aspects, is com-
monly considered to play a major role in the pathophysiol-
ogy of irritable bowel syndrome (IBS) [17,18]. Various
studies have evaluated the underlying mechanisms of visc-
eral hypersensitivity and the influence of various stresses
on the visceral pain pathways [17,18]. Recent studies have
revealed the activation of ERK in spinal cord after noxious
visceral stimulation [19,20].
ERK, a MAPK, could play a role in regulating nocicep-
tive activities in primary sensory pathways after pathologic
irritation of the peripheral system, such as peripheral
nerve injury or inflammation [21-23]. Phosphorylation of
ERK is observed in spinal dorsal horn neurons in response
to noxious stimulation of the peripheral tissue, such as the
injection of complete Freund’s adjuvant (CFA) into a hind-
paw [22], an intense noxious peripheral or C-fiber electri-
cal stimulus [21], L5 spinal nerve ligation [23], and the
injection of cyclophosphamide into the urinary bladder
[24]. ERK was also shown to be phosphorylated in the
spinal cord of a murine model of visceral pain and hyper-
algesia, intracolonic instillation of either capsaicin or mus-
tard oil [25], and in a model of acute inflammation and
distention of the colon [26]. Intrathecal injection of speci-
fic inhibitor (U-0126 or PD-98059), which specifically
attenuates ERK activity, can reduce nociceptive response
behavior in the inflammatory pain, CFA-induced joint
inflammation [27], and visceral pain by intracolonic capsa-
cin [19]. These studies suggest an essential role of ERK in
the development and maintenance of inflammatory or
neuropathatic hyperalgesia. However, very little is known
about the molecular signaling mechanisms evoked by
acute visceral pain and there is no information on the
involvement of ERK in the spinal processing in this type of
pain.
The present study focused on the role of minocycline on
spinal ERK in modulating acute visceral pain. The study
hypothesis was that minocycline attenuates the acetic
acid-induced visceral nociception by inhibiting the phos-
phorylation of neuronal ERK in the spinal cord.
Results
Minocycline inhibits acetic acid-induced abdominal
contraction
Acetic acid injection into the abdomen produces an acute
visceral pain response [28]. In this study, for the 60 min-
utes following acetic acid administration (1.0%, 250 μl),
the number of abdominal constrictions or writhes, such as
lengthwise stretches of the torso with a concomitant
concave arching of the back [28], were counted and
totaled every 5 minutes. Saline-treated mice showed the
typical abdominal stretching and constriction behaviors,
which peaked at 10-15 minutes (15.1 ± 1.2), and then gra-
dually declined. However, the peak pain responses by peri-
toneal irritation were significantly inhibited by
pretreatment of minocycline in a dose dependent manner
(4 mg/kg, 11.0 ± 1.5; 10 mg/kg, 6.1 ± 1.1; 40 mg/kg, 3.5 ±
0.8) (Figure 1A). The total number of writhing responses
during the 60 minutes after acetic acid injection in the sal-
ine pretreatment group was 84.5 ± 8.7. However, the total
number of writhes was significantly decreased by pretreat-
ment of minocycline in a dose dependent pattern (4 mg/
kg, 52.7 ± 4.6; 10 mg/kg, 32.0 ± 3.3; 40 mg/kg, 18.9 ± 3.5)
(Figure 1B). Intraperitoneal (i.p.) injection of either saline
or minocycline by themselves did not alter the behavior of
the animals (data not shown). The results suggest that
minocycline has an anti-nociceptive effect on acetic acid-
induced acute visceral pain.
Minocycline reduces acetic acid-induced c-Fos expression
Because c-Fos, an immediate early gene protein product, is
a neuroactive marker that can be used to analyze nocicep-
tive pathways [25,29,30], we compared c-Fos expression
between the saline- or acetic acid-treated mice (n = 8, in
each group) after the time at which acetic acid maximally
affected visceral pain (30 minutes after acetic acid injec-
tion) (Figure 1). c-Fosimmunoreactivity (IR) was evaluated
in the T5-L2 spinal cord where primary afferents from
splanchnic nerves innervate the entire gastrointestinal
tract [17,31]. c-Fos-IR in the spinal cord was very scarce in
normal mice (saline-administration alone) (I-X, 41.7 ± 2.2;
I-II, 5.9 ± 0.5; III-IV, 24.0 ± 1.3; V-VI, 5.5 ± 0.6; VII-IX,
5.3 ± 0.6; X, 1.0 ± 0.1). The number of c-Fos positive cells
in T5-L2 spinal cord was extensively increased by i.p.
injection of acetic acid (I-X, 187.2 ± 5.0; I-II, 36.3 ± 1.9;
III-IV, 69.2 ± 2.3; V-VI, 34.8 ± 1.3; VII-IX, 37.8 ± 1.7; X,
9.3 ± 0.5), but acetic acid-induced c-Fos-IR enhancement
was significantly decreased by minocycline-pretreatment 1
hour prior to acetic acid administration (I-X, 114.2 ± 3.1;
I-II, 21.6 ± 1.3; III-IV, 40.3 ± 1.3; V-VI, 22.8 ± 1.0; VII-IX,
24.1 ± 1.2; X, 5.4 ± 0.4). Minocycline, itself did not exert
any effect on c-Fos expression in the spinal cord (Figure
2C). Taken together, the results suggest that minocycline
has an inhibitory action for the excitation of spinal neu-
rons in acetic acid-induced acute visceral pain. In addition,
to investigate whether c-FOS was specifically activated in
the T5-L2 spinal cord, we compared the expression of c-
Fos in the samples from C1-C7, T5-L2 and L4-S1 spinal
cord 30 minutes after acetic acid injection. c-Fos expres-
sion was upregulated in the T5-L2 levels, but not in the
C1-C7, L4-S1, and normal T5-L2 segments (Additional
file 1: Figure S1).
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Page 2 of 13Figure 1 Systemic administration of minocycline inhibits acetic acid-induced abdominal pain. (A) Time course of 1% acetic acid (250 μl, i.
p.)-induced visceral pain behavior (mean ± SE). Number of abdominal constrictions after acetic acid administration was significantly inhibited by
pretreatment of minocycline in a dose dependent manner. (B) Total abdominal constrictions were attenuated by minocycline in a dose-related
fashion following i.p. injection of acetic acid. Values are expressed mean ± SEM. *, P < 0.01 versus control group (saline-pretreated and acetic
acid-treated animals (ANOVA test with a Fisher’s post hoc test)
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Page 3 of 13Figure 2 Representative photomicrographs and graph showing immunoreactivity (IR) of c-Fos in the spinal cord (T5-L2). (A, B) c-Fos
expression in the spinal cord of the saline/minocycline-pretreated and acetic acid-treated animals. Insets are high magnification of the open
rectangles. The spinal gray matter was divided into the following four regions: (1) laminae I-II, (2) laminae III-IV, laminae V-VI, (4) laminae VII-IX, (5)
laminae X. The scale bar denotes 100 μm. (C) The number of c-Fos positive cells in spinal cord following minocycline pre-injection. The
enhancement in the number of c-Fos positive cells produced by acetic acid was significantly decreased in spinal cord by minocycline pre-
administration. The mean number of c-Fos positive cells was calculated by averaging the total numbers of each region per each section/region.
Values are expressed mean ± SEM.
+, p < 0.01 versus normal group; *, p < 0.01 and **, p < 0.05 versus control group (ANOVA test with a Fisher’s
post hoc test)
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ERK expression
It has been demonstrated that spinal ERK is activated in
experimental visceral pain models [19,26,27]. Therefore,
we investigated whether minocycline could produce its
effects through the spinal ERK pathway in the acetic acid-
induced acute visceral pain. As shown in Figure 3A, 30
minutes after acetic acid administration, phosphorylation
of ERK was clearly evident in the T5-L2 spinal cord. How-
ever, the elevated level of phospho (p)-ERK was decreased
by minocycline-administration (Figure 3A). In addition,
we examined the spinal distribution of p-ERK expression
(Figures 3B-E). Immunohistochemical analysis indicated
that p-ERK positive cells in the T5-L2 spinal cord were
very scarce in saline-administrated mice (I-X, 13.2 ± 3.4)
(Figures 3B, E). The number of p-ERK positive cells in the
lamina I to X of the spinal cord was significantly increased
by acetic acid-administration (I-X, 46.7 ± 3.4), but these
acetic acid-stimulated p-ERK enhancement was signifi-
cantly decreased by minocycline-pretreatment (I-X, 26.9 ±
1.3) (Figures 3C-E). To investigate the nature of the p-
ERK positive cells, we examined whether ERK was acti-
vated in neuron, microglia, or astrocytes using multiple
immunofluorescence method. Interestingly, the p-ERK
immunofluorescence in the spinal cord from saline-treated
mice was found exclusively in neuron (83.4%; 243 p-ERK
IR and NeuN IR neurons/290 p-ERK IR neurons) (Figures
4AC), but was not clear in microglia or astrocytes (Figures
4D-I). Microglia and astrocytes were not sufficiently acti-
vated 30 minutes after acetic acid treatment (Figures 4E,
H, J and 4K). These results suggest that minocycline
attenuates neuronal ERK activation in the acetic acid-
induced acute visceral pain. In addition, to investigate
whether p-ERK is specifically increased in T5-L2 spinal
segments, we compared the expression of p-ERK in the
samples from C1-C7, T5-L2 and L4-S1 spinal segments 30
minutes after acetic acid injection. As expected, the phos-
phorylation of ERK was specifically increased in the T5-L2
levels, but not in the C1-C7, L4-S1, and normal T5-L2
spinal segments (Additional file 1: Figure S1).
Microglia and astrocytes are not morphologically
activated by acetic acid treatment
Because spinal glia (microglia and astrocytes) are acti-
vated in inflammatory pain [15,32,33] and neuropathic
pain [12,34-36], and since minocycline attenuates beha-
vioral hypersensitivity through the inhibition of micro-
glial activation in these pain models [12,15,32], we
examined whether spinal microglia and astrocytes were
activated by acetic acid and, if so, whether the activated
spinal microglia could be inhibited by minocycline pre-
treatment. Activated microglia usually display CD11/b or
Iba-1 (a marker for microglia/macrophage lineage cells)-
IR with enlarged cell body and much shorter and thicker
processes [15,37]. However, when we analyzed CD11/b
positive cells 30 minutes following acetic acid injection,
microglial activation by acetic acid was not clearly found
compared to normal mice (Figures 4E, J). In addition, we
also confirmed that astrocytes similar to microglia were
not enough activated 30 minutes following acetic acid
injection, using glial fibrillary acidic protein (GFAP) anti-
serum (Figures 4H, K). The results indicate that the mor-
phology of spinal microglia and astrocytes are not
distinctly influenced by either acetic acid in acute visceral
pain, and that spinal microglia and astrocytes do not
directly contribute to acute visceral pain.
Intrathecal administration of PD-98059 reduces acetic
acid-induced abdominal constriction
After acetic acid administration, abdominal pain response
was increased and p-ERK expression was up-regulated
mainly in spinal neurons, but not in glial cells, and the ele-
vated pain response and p-ERK expression was reduced by
pretreatment of minocyclin (Figures 1 and 4). This obser-
vation suggests that neuronal p-ERK expression contri-
butes to acetic acid-induced abdominal pain. To address
this issue, we directly introduced PD-98059, an ERK
upstream kinase (MEK) inhibitor, to normal mice
intrathecally 20 minutes before the injection of acetic acid.
In the vehicle-treated mice, the number of acetic acid-
induced writhes peaked at 10-15 minutes (16.7 ± 3.1) then
gradually declined. The total number of writhes was
78.0 ± 10.5 for 60 minutes, similar to the result of Figure 1
(Figure 5A, B). However, these abdominal pain responses
and total number of writhes were almost completely
blocked by pretreatment of PD-98059 in a dose dependent
manner at the peak time (0.1 μg, 5.6 ± 2.2;
0.5 μg, 2.6 ± 1.1) and total number of writhes (0.1 μg,
42.4 ± 15.6; 0.5 μg, 14.6 ± 5.2) (Figures 5A, B). These
results indicate that intrathecal introduction of PD-
98059 inhibits acetic acid-induced abdominal pain.
Discussion
In this study, we investigated the potential of minocycline
as an analgesic for acute visceral pain. Using the writhing
test as an experimental model, we examined the effect of
minocycline on acetic acid-induced pain response and
spinal mechanism. The results indicate that (1) ERK acti-
vation is involved in nociceptive behavior and the excita-
tion of spinal neurons in acetic acid-induced acute
abdominal pain, (2) almost all cells with ERK activation
are spinal neurons (T5-L2), (3) minocycline administrated
1 hour before acetic acid injection into the peritoneum
markedly decreases c-Fos and p-ERK expression in the
spinal cord (Figures 2 and 3), and (4) the intrathecal intro-
duction of the MEK inhibitor, PD-98059, reduces acetic
acid-induced abdominal pain (Figure 5). Collectively the
data indicate that the ERK activation is involved in the
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Page 5 of 13Figure 3 Activation (phosphorylation) of spinal ERK1/2 after saline or minocycline pretreatment. (A) Western blots of spinal tissue (T5-L2).
N, normal. AA, saline-pretreated and acetic acid-treated mice, M, minocycline alone. M + A, minocycline-pretreated and acetic acid-treated mice.
(B-D) Immunohistochemistry of spinal tissue from normal animals (B), saline-pretreated and acetic acid-treated mice (C), minocycline-pretreated
and acetic acid-treated mice (D). Insets are high magnification of the open rectangles. The scale bar denotes 100 μm. (E) The number of p-ERK
positive cells in spinal cord (T5-L2) following minocycline pre-injection. The enhancement in the number of p-ERK positive cells produced by
acetic acid was significantly decreased in spinal cord by minocycline pre-administration. The mean number of p-ERK positive cells was calculated
by averaging the total numbers of each region per each section/region. Values are expressed mean ± SEM.
+, p < 0.01 versus normal group; *, p
< 0.01 and **, p < 0.05 versus control group (ANOVA test with a Fisher’s post hoc test)
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Page 6 of 13pain behavior and neuronal response of acute abdominal
pain, and that minocycline remarkably attenuates acute
abdominal pain behavior and spinal c-Fos-IR, and that
these effects might be a consequence of reduced spinal
ERK activations.
As in other areas of pain research, the use of animal
models is a necessary step to elucidate the underlying
neurophysiological and neuropharmacological mechan-
isms of visceral pain. Over the past few years, a number
of animal models have been developed that, to a large
extent, mimic the nociception originating in the viscera
[18,31]. These models have helped advance our under-
standing of the acute physiological responses associated
with mechanical or inflammatory visceral nociception. It
has become apparent that visceral pain and somatic pain
are different, although some similarities exist [31]. In the
present study, used the acetic acid-induced nociceptive
model was developed for the screening of analgesic drugs
and described as the writhing test [38] to exam the anti-
nociceptive effect of minocycline in acute visceral pain. I.
p. injection of acetic acid is a well known noxious chemi-
cal visceral stimulus in animals [38-44]. The nociceptive
stimulation of the peritoneum by i.p. acetic acid produces
abdominal contractions or writhes, and gastrointestinal
ileus characterized by inhibition of gastric emptying and
small intestine transit. Both procedures are associated
with visceral pain [45-47]. This model is also used as a
model of somatic-visceral pain [48,49].
In a recent study, systemically administered minocy-
cline (15, 30, 45, or 100 mg/kg) reduced carrageenan- or
Figure 4 Representative photomicrographs showing immunoreactivity (IR) of phospho-ERK (p-ERK) in the spinal dorsal horn (T12-L5).
(A-I) p-ERK and NeuN immunoreactivity in the spinal dorsal horn of the saline-pretreated and acetic acid-treated mice. The p-ERK
immunofluorescence was found exclusively in spinal neuron (C; merged image), but not in microglia (D, p-ERK; E, CD11/b; F, merged image) or
astrocytes (G, p-ERK; H, GFAP; I, merged image). (J, K) Microglia (J, CD11/b) and astrocytes (K, GFAP) in normal mice. The scale bar denotes 50 μm
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Page 7 of 13Figure 5 Administration of PD-98059 inhibits acetic acid-induced abdominal pain. (A) Time course of 1% acetic acid (250 μl, i.p.)-induced
visceral pain behavior (mean ± SE). Number of abdominal constrictions (writhes) after acetic acid administration was significantly inhibited by
intrathecal pretreatment of PD-98059 in a dose dependent manner. (B) Total abdominal constrictions were remarkably attenuated by intrathecal
administration of PD-98059 in a dose-related fashion following i.p. injection of acetic acid. *, P < 0.01 versus control group (vehicle-pretreated
and acetic acid-treated animals). (ANOVA test with a Fisher’s post hoc test)
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Page 8 of 13formalin-induced paw edema, formalin-induced inflam-
matory nociceptive responses, and tactile hypersensitiv-
i t yb yf o l l o w i n gt h es e n s o r yn e r v ei n j u r y[ 1 5 , 5 0 ] .I nt h e
present study, minocycline (4, 10, or 40 mg/kg), when
intraperitoneally administrated 1 hour before acetic acid
injection reduced writhing behavior in a dose dependent
pattern (Figure 1). However, interestingly, a previous
publication reported the contradictory results; a single
dose of minocycline (30 or 100 mg/kg, i.p.) 30 minutes
before acetic acid or zymosan injection did not attenu-
ate the nociceptive behavior in mice. It had no effect on
the early events of peritoneal inflammation (vascular
permeability, inflammatory cell infiltration, and release
of pro-inflammatory cytokines) in acetic acid or zymo-
san-injected mice. In addition, minocycline did not alter
basal nociceptive responses in the tail immersion test
[51]. They used male Swiss mice (20-26 g), and we used
male ICR mice (20-25 g), they administrated minocy-
cline 30 minutes prior to nociceptive stimuli, and we
injected 1 hour before acetic acid stimulation, and they
prepared minocycline by suspension them in one or two
drops of Tween 80 in normal saline and we used normal
saline. Furthermore, it has been reported that the con-
centration of minocycline in brain peaks at 1-2 hours
after i.p. injection in phosphate buffered saline [52]. We
suggest that differences in animal strain, preparation of
drug, and duration for drug delivery could influence the
nociceptive response.
c-Fos, an immediate-early gene protein product, is a
neuroactive marker that can be used to indicate the activ-
ity of the spinal and supraspinal structures by many kind
of peripheral pain including the visceral pain [49,53,54].
Previous studies showed that acetic acid enhanced cen-
tral sensitivity with number of c-Fos-immunoreactive
nuclei in the spinal cord [49,55]. Recent studies showed
that ERK phosphorylation by noxious stimuli contributes
to the neuronal c-Fos expression in the spinal cord. ERK
phosphorylation is involved in the establishment as well
as maintenance of long-term neuronal alterations asso-
ciated with chronic pain following noxious stimulation,
such as c-fiber/capsaicin stimulation [56], chronic con-
strictive injury-induced neuropathic pain [57], noxious
bladder stimulation [58], and colorectal distension stimu-
lation [26]. In this study, p-ERK expression was consis-
tent with the high expression of c-fos in the laminae I-X
of the spinal segments (T5-L2) which innervate gastroin-
testinal tract. These results suggest that ERK activation is
correlated with the expression of spinal c-Fos in acetic
acid-induced mice.
Phosphorylation of spinal ERK has a substantial role in
nociception [22,59,60]. Recent studies have shown that
ERK phosphorylation in the spinal dorsal horn neurons
might also participate in some visceral pain processing by
in a model of visceral pain and hyperalgesia induced by
cororectal distension [61], bladder hyperalgesia by cyclo-
phosphamide [20] and intracolonic instillation of irritants
(capsaicin, mustard oil) in adult mice [19]. However, the
role of spinal ERK in response to acetic acid-induced
acute visceral pain has not been previously described.
Our study clearly demonstrates that acetic acid can
rapidly induce phosphorylation of ERK in the spinal cord
(Figure 3). The p-ERK-IR neurons were specifically loca-
lized to T5-L2 segments, which is consistent with gastro-
intestinal innervations [17]. Therefore, we suggest that
phosphorylation of spinal ERK is responsible for nocicep-
tive transmission from the gastrointestinal tract stimu-
lated by acetic acid.
Spinal microglia are activated in inflammatory and neu-
ropathic pain [15,24]. Activated microglia secrete proin-
flammatory mediators such as prostaglandins, proteases,
excitatory amino acids and cytokines such as tumor necro-
sis factor-alpha, interleukin (IL)-1b,a n dI L - 6 ,a n dt h e
released substances participate in pain processing [52].
Recently, it has been demonstrated that minocycline
attenuates the development of pain hypersensitivity by the
inhibition of microglial activation and proinflammatory
cytokine expression in inflammatory and neuropathic pain
[11,24]. Our previous studies confirmed that minocycline
attenuates tactile hypersensitivity following trigeminal sen-
sory nerve injury through the inhibition of microglial p38
MAPK activation [60], and that minocycline markedly
reduces formalininduced inflammatory pain by inhibition
of EPSCs in the substantia gelatinosa [15]. Recently, it was
reported that minocycline completely reverses mechanical
hyperalgesia in diabetic rats through microglia-induced
changes in the expression of the potassium chloride co-
transporter 2 (KCC2) at the spinal cord [13]. These find-
ings raise the possibility that minocycline may behave as a
potential analgesic for other types of pain model. There-
fore, in the present study, we examined the anti-nocicep-
tive effects of the minocycline in an acetic acid-induced
acute visceral pain models. The results show that minocy-
cline attenuates behavioral hypersensitivity through the
inhibition of neuronal ERK activation in the spinal cord of
acute visceral pain.
After peripheral nerve inflammation or injury, spinal
microglia is initially activated and subsequently the sus-
tained activation of astrocytes is precipitated. Activated
astrocytes, as well as microglia, produce proinflammatory
cytokines and chemokines, which are implicated in the
induction and maintenance of pathological pain [62]. In
our immunohistochemical study, the morphological acti-
vation of microglia and astrocytes were not clear 30 min
after acetic acid injection, compared to normal brain
(Figure 4). These findings agree with previous reports
that the activation of microglia and astrocytes were not
discernable as early as 1 h following formalin injection
(acute pain) [15,33,63] and 2 h following the transection
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tively. But in these reports, activated microglia and astro-
cytes were only increased after 1 day and peaked 3-7 days
following formalin injection or peripheral nerve transec-
tion [14,15,33,63]. Therefore, our findings suggest that
microglia and astrocytes might not be a causal factor in
the central hypersensitivity of acetic acid-induced acute
visceral pain.
MAPKs signalling pathways are likely important
mechanism for development and maintenance of central
sensitization [64,65]. The anti-nociceptive effect of an
ERK upstream kinase (MEK) inhibitor, PD-98059, has
been reported in various pain models including chronic
constriction injury [66], complete Freund’sa d j u v a n t -
induced monoartritis [67], and formalin-, capsaicin-, or
mustard-induced inflammatory pain [19,21]. More
recently, it was reported that increased spinal ERK1/2
phosphorylation in 3-week monosodium iodoacetate
(MIA)-osteoarthritis (OA) rats was blocked by the PD-
98059, when examined 30 minutes following acute
intrathecal administration [68]. Moreover, the observa-
tions in MIA-OA rats that PD-98059 treatment partially
blocks pain behaviour and reduces grip force strength
[68] supports the potential involvement of ERK1/2 phos-
phorylation in the dorsal horn spinal cord in mediating
nociceptive-induced central sensitization associated with
this model of osteoarthritis. In the present study, because
the acetic acid-stimulated acute abdominal pain was
reduced by inhibiting neuronal p-ERK expression in
spinal cord by pretreatment of minocycline (Figure 3), we
studied whether the directly introduction of PD-98059 to
subarachnoid space could reduce the acetic acid-induced
acute abdominal pain. Consistent with previous findings,
we confirmed that the intrathecal pre-administration of
PD-98059 markedly blocks the excitation of spinal neu-
ron in the mouse model of acetic acid-induced acute
abdominal pain.
It is interesting to note that minocycline inhibits the
early activation of neuronal ERK MAPK in spinal cord
although the effect of minocycline is generally considered
to be on glia. Based on the early/acute response of the
visceral pain, the acute inhibitory effect of minocycline on
ERK activation might not be due to its inhibitory actions
on spinal glial activation. Minocycline might have a direct
inhibitory effect on neuronal ERK rather than glial ERK.
Thus, these results suggest that the anti-nociceptive effect
of minocycline for acute visceral pain is associated with
neuronal ERK activation in the spinal cord.
Conclusions
Increased spinal ERK phosphorylation is important for
pain behaviors based on the MEK inhibitor studies.
However, the direct link between minocycline’s inhibi-
tory effects in visceral nociceptive responses and its
modulating effects on p-ERK expression has been
unclear. In this study, minocycline attenuated the
abdominal nociception, and the activation of spinal c-
Fos and ERK 1/2 in the acetic acid-induced acute visc-
eral pain. The intrathecal introduction of PD-98059, a
MEK inhibitor, reduced the nociceptive behavior by
acetic acid. These results strongly suggest that minocy-
cline has an anti-nociceptive effect on acetic acid-
induced acute visceral pain by inhibiting neuronal ERK
activation in the spinal cord.
Methods
Animals
The male ICR mice (weight, 20-25 g) were kept at a con-
stant temperature of 23 ± 2°C with a 12-h light-dark cycle
(light on 08:00 to 20:00), and fed food and water ad libi-
tum. The animals were allowed to habituate to the hous-
ing facilities for 1 week before the experiments. All
experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) in College of Oriental
Medicine, Kyung Hee University and animal treatments
were performed according to the guidelines of the Interna-
tional Association for the Study of Pain [69].
Acetic acid-induced writhing test
The acetic acid-induced visceral pain model is widely used
in experimental research to produce abdominal contrac-
tions [38-44]. Mice were randomly assigned to two groups,
saline-treated group (control group, n = 12) and minocy-
cline-treated group (n = 31). Minocyclinetreated mice
received minocycline (Sigma-Aldrich, U.S.A.) either 4 mg/
kg (n = 10), 10 mg/kg (n = 10) or 40 mg/kg (n = 11) intra-
peritonially (i.p.) 1 hour before acetic acid i.p. injection
(1.0%, 250 μl), respectively. Control mice received an equal
volume of saline vehicle. The dosage of minocycline was
determined based on the previous reports of therapeutic
effects of minocycline [3,4,10,12,15]. The time point of
acetic acid injection was determined based on a previous
report of optimal delivery of minocycline in rats [70]. Fol-
lowing the i.p. injection of acetic acid, mice were placed in
a clear plastic cage (20 × 26 × 12 cm), and the number of
writhes per mice was counted in 5 minutes interval for 60
minutes. The behavioral tests were performed blinded
under the constant condition (temperature, 23 ± 2°C;
humidity, 55 ± 5%) between 9:00 am and 12:00 am in a
quiet room.
Immunocytochemical evaluation
At 30 minutes after the i.p. injection of acetic acid, the
mice used for immunohistochemistry (n = 8/group) were
anesthetized with 40 mg/kg sodium pentobarbital (i.p.),
and perfused with fresh 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). The T5-L2 spinal segment
was removed and postfixed at 4°C overnight and then
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sucrose for 48 hours at 4°C. Immunostaining was carried
out according to previously established procedures
[15,37]. Briefly, cryosections (10 μm thickness) were
mounted onto gelatin-coated slide glass. Six transverse
sections in 700 μm intervals were selected from each ani-
mal [saline, n = 8; minocycline (40 mg/kg), n = 8] and
incubated for 30 minutes with 3% H2O2,a n dt h e n
blocked with a solution containing 5% normal goat/or
horse serum, 2% BSA, 2% FBS and 0.1% triton X-100 for
2 hours at room temperature (RT). The sections were
incubated overnight at 4°C with either rabbit anti-c-Fos
(1:10,000; Oncogene, U.S.A.), or rabbit anti-phospho
ERK (1:500; Cell Signaling, U.S.A.). Sections were then
incubated with biotinylated rabbit IgG antibody (1:200;
Vector Laboratories, U.S.A) for 1 hour at RT. After rin-
sing, the sections were incubated with avidin-biotinylated
HRP complex (1:200; Vector Laboratories, U.S.A) for
1 hour at RT and visualized with DAB. Sections were
rinsed, and dehydrated and cover-slipped. Immunos-
tained images were captured using image system (DP 70
digital camera, Olympus, Japan) under light microscope.
Photo-images from the right side of T5-L2 were drawn
using manual technique, and the numbers of c-Fos posi-
tive cells were counted. Each section was divided into (1)
superficial dorsal horn (laminae I-II), (2) deep dorsal
horn (laminae III-IV), (3) neck region (laminae V-VI), (4)
ventral horn (laminae VII-IX), and (5) central canal
region (lamina X) [71]. Evaluation of the immunostained
sections were performed by an experimenter unaware of
the experimental condition.
Immunofluorescence evaluation
For double immunofluorescent staining, sections were
incubated overnight at 4°C with a mixture of rabbit
anti-p-ERK antibody (1:500; Cell Signaling, U.S.A.) and
mouse anti-NeuN (1:500; Chemicon, U.S.A)/or rat/
mouse anti-CD11/b (1:200; Serotec, U.S.A.)/GFAP
(1:1,000; Chemicon, U.S.A) antibody. The sections were
then incubated for 1 hour at RT with mixture of Cy3-
and FITC-conjugated rabbit/rat/mouse IgG antibody
(1:200; Jackson ImmunoResearch, U.S.A.), and then
examined with confocal imaging system (LSM 5 PAS-
CAL; Carl Zeiss, Germany).
Western blot analysis
To investigate the level of p-ERK expression, minocycline
(40 mg/kg) was injected intraperitoneally 1 hour before
the i.p. injection of acetic acid. And at 30 minutes after the
i.p. injection of acetic acid, the mice used for Western blot
analysis (n = 4/group) were anesthetized, and the C1-C7,
T5-L2, and L4-S1 spinal segments were removed with
lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1%
Triton X-100, 10% glycerol, and protease inhibitor
mixture). A total of 50 μg of tissue lysate from each sam-
ple was resolved by electrophoresis on a 10% SDS-PAGE.
The proteins were then transferred to PVDF membranes
and blocked with 5% nonfat dry milk in Tween 20-con-
taining Tris-buffered saline (TBST, 20 mM Tris, pH 7.4,
0.1% Tween 20, and 150 mM NaCl). The membranes
were probed overnight with rabbit anti-c-Fos (1:1,000;
Merck KGaA, Germany) or rabbit anti-p-ERK (1:2,000;
Cell Signaling, U.S.A.) antibodies at 4°C, which was
followed by incubation with HRP-conjugated secondary
antibody at RT for 1 hour prior to enhanced chemilumi-
nescence ECL (Amersham Pharmacia Biotech, U.S.A.)
treatment and exposure to x-ray film. For normalization of
antibody signal, the membranes were stripped and
reprobed with antibodies for actin (1:2,000; Santa Cruz,
U.S.A.) or ERK 1/2 (1:2,000; Cell Signaling, U.S.A.). After
Western blot was performed several times, the density of
each band was converted to numerical values using an
Adobe Photoshop CS2 program (Adobe, San Jose, CA,
U.S.A.), subtracting background values from an area of
film immediately adjacent to the stained band. Data are
expressed as the ratio of c-Fos or p-ERK against actin or
total ERK 1/2 for each sample.
Intrathecal (i.t.) administration of PD-98059
The i.t. injections were performed under light isofluran
anesthesia (1-2%). The dorsal fur of each mouse (saline +
acetic acid, n = 10; 0.1 μg PD-98059 + acetic acid, n = 8;
0.5 μg PD98059 + acetic acid, n = 10) was shaved, the
spinal column was arched, and a 30-gauge needle was
directly inserted into the subarachnoid space, between the
L5 and L6 vertebrae [72]. Correct i.t. positioning of the
needle tip was confirmed by manifestation of a character-
istic tail flick response. The 0.1 and 0.5 μg of PD-98059
(2-amino-3’-methoxyflavone; Calbiochem, USA), an ERK
upstream kinase (MEK) inhibitor, or vehicle (saline alone
or 10% DMSO) were slowly injected into the mice with a
50 μl Hamilton micro syringe in a total volume of 5 μl.
The entire injection procedure, from the induction of
anesthesia until recovery of consciousness, took 4-5 min-
utes. Preliminary injections were performed with a similar
volume of 10% India ink solution, and then the reliability
and accuracy of this method was confirmed by subsequent
dissection of the lumbar spinal cord. The success rate for
the prior injections with this technique was over 97.5%.
The same investigator performed all injections. The i.p.
injections of acetic acid and behavioral test were per-
formed 20 minutes after i.t. injection of PD-98059, as
described above.
Statistical analysis
The statistical significance of differences between the
values was determined using an ANOVA with a Fisher’s
post hoc test. All data are presented as the mean ± S.E.
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unless indicated otherwise.
Additional material
Additional file 1: Figure S1. Expression of c-Fos and p-ERK in the spinal
cord of acetic acid-induced visceral pain models. c-Fos (A, B) and p-ERK
(C, D) are specifically upregulated in the T5-L2 spinal segments of acetic
acid-treated mice. Values, expressed as relative intensities, represent the
mean ± SEM. *P < 0.01 versus five control groups except acetic acid-
treated T5-L2 segments (ANOVA test with a Fisher’s post hoc test). S,
saline-treated normal mice; AA, acetic acid-treated mice.
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